30 April 2020

Safety Updates & Recalls of Pharmaceutical Products & Medical Devices

Reference: CIR-2019-00000369

To all health facilities / all health care practitioners in Dubai's private health sector:

Referring to the above subject, DHA notes all health facilities regarding the Circular issued by the MOHAP for information and adhere to what is stated

• Precautionary Recall & Suspension of registration for all Ranitidine drugs
• Recall Medical Device 6 French Sherpa NX Active Guide Catheters
• Safety update of a pharmaceutical products containing Ondansetron
• Safety Alerts for medical device BD Max™ Reagents
• Recall & Suspension of registration for Pharmaceutical Products

 

Thanks in advance for your good co-operation

Drug Control Section

Health Regulation Sector

DHA

Supporting Documents:

Precautionary Recall _ Suspension of registration for all Ranitidine drugs.pdf:

View Document

Recall _ Suspension of registration for Pharmaceutical Products.pdf:

View Document

Safety Alerts for medical device BD Max™ Reagents.pdf:

View Document

Safety update of a pharmaceutical products containing Ondansetron.pdf:

View Document

Recall Medical Device 6 French Sherpa NX Active Guide Catheters.pdf:

View Document